Group 1 - The core viewpoint of the news is that Guichuang Tongqiao (02190) has reported significant growth in its interim results, with a notable increase in revenue and profit, driven by its vascular intervention product lines [1][2] - For the six months ending June 30, 2025, the company reported revenue of 482 million RMB, a year-on-year increase of 31.69%, and a gross profit of 343 million RMB, also up by 31.5% [1] - The net profit attributable to shareholders reached 121 million RMB, marking a substantial increase of 76% year-on-year, with basic earnings per share at 0.38 RMB [1] Group 2 - The company’s revenue composition shows that 63.3% comes from neurovascular intervention products, while 36.7% is from peripheral vascular intervention products, indicating a strong performance in both segments [1] - Guichuang Tongqiao has been actively expanding its international presence, particularly in Europe, with successful penetration into markets such as France, Germany, and Italy, as well as emerging markets like Brazil, India, and South Africa [2] - The international business achieved revenue of 15.72 million RMB in the first half of the year, reflecting a year-on-year growth of 36.9%, and is expected to see further acceleration in growth in the second half of the year [2]
港股异动 | 归创通桥(02190)涨超5% 上半年核心板块业务表现亮眼 海外布局打造新增长引擎